Roth Capital affirms Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) at Buy with a price target of $520 after the company and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Regeneron (REGN): Ready To Go On Approval Of Dupilumab BLA - RBCOctober 3, 2016 9:30 AM Regeneron (REGN), Sanofi (SNY) Announce Publication of Positive Dupixent Phase 3 Data as AD TreatmentOctober 3, 2016 6:32 AM Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of MedicineOctober 1, 2016 2:00 AM